Skip to main content

Revolutionary Advances in Genomic Cancer Panel and Profiling Markets Propel Oncology Forward -

The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size" report has been added to's offering.

The landscape of cancer diagnosis and treatment is undergoing a significant transformation, driven by the rapid evolution of Genomic Cancer Panel and Profiling technologies. These advanced methods are now transitioning from specialized applications to becoming mainstream tools in the hands of oncologists.

By harnessing information from hundreds of genes related to various cancers, these technologies are poised to revolutionize the accuracy and personalization of cancer diagnostics.

Segmented Growth and Commercial Dynamics

The genomic profiling market is experiencing exponential growth across two distinct segments: comprehensive panels and high-risk breast cancer panels. Industry players are actively seeking strategic positions in this burgeoning market, which is essentially in the process of being recreated.

With some competitors taking the lead and expanding on a global scale, there is a renewed focus on commanding a premium in a high-value, dynamic marketplace. The continuous advancements in scientific understanding of cancer genomics intersect with dropping sequencing costs to present an array of fresh opportunities.

Strategic Planning and Market Forecasting

Comprehensive data provided by Genomic Cancer Panel and Profiling Markets is an invaluable tool for analysts and strategic planners. This wealth of information, encompassing projections, detailed international breakouts, and vital capital knowledge regarding Medicare Fee Payment Schedules, is instrumental for gauging demand for emerging testing technologies and guiding research investment decisions. Hospitals and laboratories can leverage this data for clinical facilities planning, ensuring readiness to meet future diagnostic demands.

Global Outlook and Forecasting

Offering a detailed analysis for 18 countries and 4 global regions, these insights present a granular view of the market, allowing healthcare stakeholders to prepare for the advancements in cancer diagnostics. Furthermore, this report anticipates market trends over the next five years, providing a strategic forecast essential for anyone involved in the oncology sector.

With the integration of genomic profiling, the face of cancer diagnostics will be indelibly changed, offering the promise of more targeted and effective treatment modalities for cancer patients worldwide.

Companies Featured

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics (Danaher)
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bioview
  • Bristol-Myers Squibb
  • Burning Rock
  • C2i Genomics
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • Celemics
  • CellMax Life
  • Cepheid (Danaher)
  • Charles River Laboratories
  • Circulogene
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fabric Genomics
  • Fluxion Biosciences (Cell Microsystems)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GeneFirst Ltd.
  • Genetic Technologies Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • J&J Innovative Medicine
  • KEW
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene
  • Oncimmune
  • Oncocyte
  • OncoDNA
  • OraLiva
  • Oxford Nanopore Technologies
  • Panagene
  • Personalis
  • Perthera
  • PGDx (Labcorp)
  • Precipio
  • PrecisionMed
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • QuidelOrtho
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Screencell
  • Sherlock Biosciences
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Variantyx
  • Vela Diagnostics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.